Eledon Pharmaceuticals (ELDN) Accumulated Expenses (2013 - 2026)

Eledon Pharmaceuticals has reported Accumulated Expenses for 14 years, with the latest figure at $6.5 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 9.15% year-over-year to $6.5 million; the trailing twelve-month figure through Mar 2026 stood at $6.5 million (up 9.15% YoY), and the FY2025 full-year result was $14.4 million, up 164.44% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $6.5 million, down from $14.4 million in the prior quarter.
• The five-year high for Accumulated Expenses was $14.4 million in Q4 2025, with the low at $845000.0 in Q1 2023.
• Historically, Accumulated Expenses has averaged $3.6 million across 5 years, with a median of $2.3 million in 2023.
• Annual changes were most pronounced in 2022 — Accumulated Expenses surged 1153.12% — and 2025, when it sank 50.12%.
• Eledon Pharmaceuticals' Accumulated Expenses stood at $3.9 million in 2022, then tumbled by 34.94% to $2.5 million in 2023, then jumped by 113.36% to $5.4 million in 2024, then jumped by 164.44% to $14.4 million in 2025, then plunged by 54.7% to $6.5 million in 2026.
• The last three Accumulated Expenses figures came in at $6.5 million (Q1 2026), $14.4 million (Q4 2025), and $3.2 million (Q3 2025), per Business Quant data.